TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE

癌症的靶向分子成像对于更好的个性化医疗至关重要，但需要识别关键分子表面细胞标记物的新型成像剂。Her 2在20-30%的乳腺癌中过表达，并被赫赛汀靶向，但临床上没有批准Her 2的分子成像剂。我们建议使用扫描非天然蛋白酶抗性（SUPR）肽开发一种新的Her 2特异性放射性示踪剂的PET/CT。SUPR肽显示抗体样亲和力、对蛋白水解和代谢修饰的抗性以及从体循环中的快速清除，使其成为理想的成像剂。首先，将针对Her 2特异性肿瘤摄取小鼠筛选用近红外光学染料修饰的抗Her 2 SUPR肽。然后，我们将合成[18F]标记的SUPR肽，通过PET/CT对Her 2过表达肿瘤进行成像。EvoRx Technologies将与MD安德森癌症中心合作，将SUPR肽快速转化为强大的核成像工具，推进乳腺癌的个性化治疗。

Targeted molecular imaging of cancer is vital for better personalized medicine, but requires novel imaging agents that recognize key molecular surface cell markers. Her2 is overexpressed in 20-30% of breast cancer and is targeted by Herceptin, yet no molecular imaging agent for Her2 is clinically approved. We propose to use Scanning Unnatural Protease Resistant (SUPR) peptides to develop a novel Her2-specific radiotracer for PET/CT. SUPR peptides show antibody-like affinities, resistance to proteolytic and metabolic modification, and rapid clearance from systemic circulation, making them ideal imaging agents. First, Anti-Her2 SUPR peptides modified with a near-infrared optical dye will be screened for Her2-specific tumor uptake mice. We will then synthesize [18F]-labeled SUPR peptides to image Her2-overexpressing tumors by PET/CT. EvoRx Technologies will collaborate with the MD Anderson Cancer Center to rapidly translate SUPR peptides into a powerful nuclear imaging tool, advancing the personalized treatment of breast cancer.